Jiangsu Yahong Meditech Management

Management criteria checks 2/4

Jiangsu Yahong Meditech's CEO is Kevin Pan, appointed in Mar 2010, has a tenure of 14.17 years. directly owns 22.83% of the company’s shares, worth CN¥888.61M. The average tenure of the management team and the board of directors is 3 years and 3.4 years respectively.

Key information

Kevin Pan

Chief executive officer

CN¥4.6m

Total compensation

CEO salary percentage	n/a
CEO tenure	14.2yrs
CEO ownership	22.8%
Management average tenure	3yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

CEO

Kevin Pan (55 yo)

14.2yrs

Tenure

CN¥4,566,500

Compensation

Dr. Kevin Pan is Founder, Chairman and Chief Executive Officer at Asieris Pharmaceuticals Co. Ltd since march 16, 2010.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Pan	Founder	14.2yrs	CN¥4.57m	22.83% CN¥ 888.6m
Chengfeng Zhuang	Deputy GM & Director	3.4yrs	CN¥2.36m	1.06% CN¥ 41.1m
Mingyuan Yang	Financial	3.4yrs	no data	0.0032% CN¥ 126.5k
David Wilson	Senior Vice President of BD	no data	no data	no data
Alice Chen	Senior VP of Discovery Biology & Head of Translational Research	2.7yrs	no data	no data
Linda Wu	Chief Development Officer	1.3yrs	no data	no data
Sophia Cao	SVP & Head of the Women's Health Business Unit	less than a year	no data	no data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Management: 688176's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Pan	Founder	14.2yrs	CN¥4.57m	22.83% CN¥ 888.6m
Chengfeng Zhuang	Deputy GM & Director	4.8yrs	CN¥2.36m	1.06% CN¥ 41.1m
Mingyuan Yang	Financial	less than a year	no data	0.0032% CN¥ 126.5k
Yinglu Guo	Honorary Chairman of Clinical Advisory Committee	no data	no data	no data
Dingwei Ye	Chairman of Clinical Advisory Committee	no data	no data	no data
Hanzhong Li	Member of Clinical Advisory Committee	no data	no data	no data
Fangjian Zhou	Member of Clinical Advisory Committee	no data	no data	no data
Zhisong He	Member of Clinical Advisory Committee	no data	no data	no data
Badrinath Konety	Member of Scientific Advisory Board	1.8yrs	no data	no data
Kan Chen	Director	3.4yrs	no data	no data
Bing Hui Zhang	Independent Director	3.4yrs	CN¥150.00k	no data
Yi Zhong	Chairman of the Supervisory Board	3.4yrs	no data	no data

3.4yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 688176's board of directors are considered experienced (3.4 years average tenure).

Jiangsu Yahong Meditech Management

Management criteria checks 2/4

Key information

Recent management updates

Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit

Asieris Pharmaceuticals Appoints Dr. Linda Wu as Chief Development Officer

Less than half of directors are independent

Asieris Pharmaceuticals Appoints Dr. Badrinath Konety to Scientific Advisory Board

Recent updates

First quarter 2024 earnings released: CN¥0.15 loss per share (vs CN¥0.11 loss in 1Q 2023)

Consensus revenue estimates increase by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Jiangsu Yahong Meditech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN

Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) announces an Equity Buyback for CNY 100 million worth of its shares.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU

Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit

Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China

Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting

Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Hong Kong Department of Health Approves the Registration Applications for the Uro-G and Uro-V DisposableCystoscopic System

Asieris Pharmaceuticals Confirms Hexvix Phase III Clinical Trial in China Meet Endpoint

Asieris Pharmaceuticals Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Asieris' Progress in MIBC Receives Renewed Attention with Its Inclusion in Asco 2023

Asieris Pharmaceuticals Appoints Dr. Linda Wu as Chief Development Officer

Asieris Pharmaceuticals' Bladder Cancer Diagnostic Drug Hexvix Completes Dosing of First Patient in Real-World Clinical Study

Less than half of directors are independent

Asieris Pharmaceuticals Obtaines IND Approval from US FDA for APL-1401, A New Drug for the Treatment of Moderately-To-Severely Active Ulcerative Colitis

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

Asieris Pharmaceuticals Announces Patient Enroll in Hexvix Phase III Trial in China

Asieris Pharmaceuticals Appoints Dr. Badrinath Konety to Scientific Advisory Board

Asieris Pharmaceuticals Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Asieris Pharmaceuticals to Present Study Protocol of APL-1202 in Combination with Beigene's Tislelizumab as Neoadjuvant Therapy For Muscle Invasive Bladder Cancer Patients At 2022 ASCO Annual Meeting

Photocure ASA Partner Asieris Pharmaceuticals Announces Approval to Conduct A Phase III Clinical Trial for Hexvix in China

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age